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1379Bare-metal stents (BMS) are still widely used in coronary
interventions, although they may be associated with the
appearance of in-stent restenosis (ISR) (1). Currently, treat-
ment of ISR remains a challenge (2–10). Many coronary
interventions have been advocated in this setting, but data
from randomized clinical trials suggest that drug-eluting stents
(DES) provide superior long-term clinical and angiographic
results (2–10). More recently, drug-eluting balloons (DEB)
have also proven to be highly effective for ISR (11–16). In pa-
tients with BMS-ISR or DES-ISR, DEB have proven to be
superior to conventional balloon angioplasty and comparable to
ﬁrst-generation DES (11–16).
New-generation DES appear to be not only more effec-
tive but also safer than ﬁrst-generation DES (17–19). In
particular, everolimus-eluting stents (EES) have demon-
strated excellent long-term clinical and angiographic results
(17–19). Notably, the clinical value of second-generation
DES has also been demonstrated in subsets of complex le-
sions, including patients presenting with ISR (8). However,
the relative efﬁcacy of second-generation DES compared
with that of DEB in patients with ISR remains unknown.
In this randomized clinical trial, we sought to compare the
results of DEB with those of EES in patients presenting
with BMS-ISR.Methods
Patient selection and study design. The RIBS V (Reste-
nosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting
Balloon vs. Everolimus-eluting Stent) study was designed
as a multicenter, prospective, open-label, active treatment-
controlled, randomized clinical trial to compare the results
of DEB with those of EES in patients with BMS-ISR
(ID: NCT01239953; for a list of participating physicians
and institutions, please see the Online Appendix). Brieﬂy,
patients with BMS-ISR (>50% diameter stenosis on visual
assessment) presenting with angina or objective evidence of
ischemia were eligible (2,4). Patients with BMS-ISR in
small vessels (2.0 mm in diameter) or very diffuse lesions
(>30 mm in length) were excluded (2,4). In addition, pa-
tients with very early (<1 month) ISR and those presenting
with an acute myocardial infarction or with images of
intracoronary thrombi also were excluded. Patients with
edge-ISR were eligible only when the stent border was
clearly affected. In those cases, the use of intracoronary im-
aging techniques was recommended to conﬁrm the involve-
ment of the stent edge. Patients with contraindications to
aspirin or clopidogrel therapy, severe renal or hepatic failure,Spain; zzzHospital Universitario Virgen de la Salud Toledo, Toledo, Spain;
xxxHospital Universitario Sant Pau, Barcelona, Spain; and the kkkHospital Uni-
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2013, accepted December 3, 2013.severe peripheral vascular disease,
life expectancy of <1 year, or any
major concomitant systemic dis-
ease potentially interfering with
clinical or angiographic follow-up
were not included.
The primary endpoint was
the in-segment minimal lumen
diameter at 9 months’ follow-up
as measured by quantitative cor-
onary angiography.
Twenty-ﬁve university hospi-tals from Spain participated in this trial (see the Online
Appendix). Telephone randomization (1:1 to DEB or
EES) was performed at the coordinating center, using a
computer-generated sequence (2,4). Patients were stratiﬁed
according to ISR length and location (edge vs. intra-stent)
based on visual assessment. Data collection, management,
and analysis were performed at the coordinating center
(Clínico San Carlos University Hospital, Madrid). The
study was an investigator-driven initiative and was con-
ducted under the auspices of the Working Group on
Interventional Cardiology of the Spanish Society of Cardi-
ology. Unrestricted research grants were obtained from both
B. Braun Surgical and Abbott Vascular. Patients and in-
vestigators were not masked to treatment allocation, but
clinical events and angiographic ﬁndings were assessed by
blinded individuals to prevent ascertainment bias. The study
was performed according to the provisions of the Declara-
tion of Helsinki, and the study protocol was approved by the
Institutional Ethics Committees of all participating centers.
Written informed consent was obtained from all patients.
Interventions. Patients were pre-treated with aspirin and
clopidogrel. A loading dose of clopidogrel (300 to 600 mg)
was administered before the intervention to clopidogrel-
naïve patients. Full anticoagulation was obtained during the
procedure with unfractionated heparin (initial bolus of 100
mg/kg, with additional boluses as required to achieve an
activated clotting time >250 s). Lesions were pre-dilated
with relatively short balloons to avoid damaging adjacent
coronary segments. Care was also taken to prevent balloon
slippage and watermelon seeding phenomena. Special
attention was given to correct underlying underexpanded
stents. In this situation, the use of noncompliant balloons at
very high pressures was recommended (4). After adequate
lesion pre-dilation, patients received the allocated treatment.
DEB (SeQuent Please, B.Braun Surgical, Melsungen,
Germany) were selected with a balloon-to-artery ratio of
1.1:1 and inﬂated at nominal pressures (12 to 14 atm) for
60 s. In this arm, cross-over to bailout stenting was allowed
only for dilation failure (>50% residual stenosis) or major
dissections. Alternatively, EES (Xience Prime, Abbott
Vascular, Abbott Park, Illinois) were implanted using a ﬁnal
balloon-to-artery ratio of 1.1:1 and relatively high pressure
(>14 bar). After EES implantation, post-dilation with
noncompliant balloons was allowed at the operator’s
Alfonso et al. JACC Vol. 63, No. 14, 2014
Drug-Eluting Balloon Versus Everolimus Stent for In-Stent Restenosis April 15, 2014:1378–86
1380discretion. The use of intracoronary imaging techniques to
assess stent expansion and optimize procedural ﬁnal results
was suggested in the protocol, but the selection of these
techniques and the ﬁnal optimization strategies were left to
the discretion of the local investigators.
Serum creatine kinase (with MB determinations when
abnormal) and troponin levels and 12-lead electrocardio-
grams were serially obtained for 24 h (4). Clopidogrel
(75 mg/day) was recommended for 1 year after EES im-
plantation and for 3 months after DEB therapy. All patients
were treated with aspirin indeﬁnitely.
Protocol, deﬁnitions, and follow-up. Patients were fol-
lowed at 6 to 9 months and at 1 year. Angiographic follow-
up was scheduled at 6 to 9 months, but it was performed
earlier if clinically indicated. Case report forms were
completed at each site by local investigators and submitted
to the coordinating center. Data were monitored and
reviewed for completeness and consistency. When required,
speciﬁc queries were sent back from the coordinating center
to the sites. All data were prospectively entered into a
dedicated, relational database designed speciﬁcally for
the RIBS studies (2,4). Clinical events (death, myocardial
infarction, and target vessel revascularization) were adjudi-
cated by an independent Clinical Events Committee that
was unaware of the therapeutic strategy, after the review of
all corresponding source documents. All deaths were
considered cardiac related unless a clear noncardiac cause
could be established. The diagnosis of myocardial infarc-
tion required 2 of the following: 1) prolonged (>30 min)
chest pain; 2) a rise in creatine kinase levels more than
twice the local upper normal value (with abnormal MB
fraction); and 3) development of persistent ischemic elec-
trocardiographic changes (with or without new patholog-
ical Q waves) (2,4). The protocol indicated that during
follow-up, all repeated interventions were required to be
clinically justiﬁed. All angiograms of patients with target
vessel revascularization were reviewed to identify target
lesion revascularization. The Academic Research Con-
sortium deﬁnition was used to assess the presence of stent
thrombosis (20).
Angiographic analysis. All coronary angiograms were
analyzed at the angiographic core laboratory by trained
personnel blinded to treatment allocation by using
standard methodology (2,4). The Mehran (21) and Amer-
ican College of Cardiology/American Heart Association
(22) classiﬁcations were used to assess lesion shape. An
automatic edge-detection system (CASS II System, Pie
Medical, Maastricht, the Netherlands) was used for ofﬂine
quantitative measurements. Carefully selected orthogonal,
angiographic views (without vessel foreshortening or side-
branch overlap) were obtained after nitroglycerin adminis-
tration. Matched projections were repeated after intervention
and at follow-up. In-lesion and in-segment (the treated
segment plus 5 mm proximal/distal margins) analyses were
performed. Reference vessel diameter, minimal lumen
diameter, percent of diameter stenosis, late loss, loss index,and binary restenosis rate (>50% diameter stenosis) were
determined.
Statistical analysis. Categorical data are presented as
percentages and were compared using the chi-square test or
Fisher exact test. Continuous data are presented as mean
 SD or medians (interquartile range) after data distribu-
tion (Kolmogorov-Smirnov test) was analyzed. The Student
t test or Mann-Whitney U test was used for the compar-
ison of continuous variables. Main effects estimates are
presented as absolute differences and 95% conﬁdence in-
tervals (CIs) after assessment of variance homogeneity.
Kaplan-Meier curves were constructed to estimate event-
free survival rates. Hazard ratios and corresponding 95%
CIs were assessed using Cox models and were compared
using the Wald test. Sample size calculations required
several assumptions based on previous data, although results
of EES in this setting were unavailable at the time of study
design. Based on the RIBS I and II trials (2,4), a minimal
lumen diameter of 2.6 mm was anticipated immediately
after stent implantation. Assuming a late loss of 0.3 mm
(2), a minimal lumen diameter at follow-up of 2.3  0.7
mm was expected. On the same basis, a minimal lumen
diameter of 2.2 mm was anticipated after DEB treatment
(2,4). Assuming a late loss of 0.2 mm (12), a minimal
lumen diameter at follow-up of 2.0  0.7 mm was calcu-
lated. Accordingly, 172 patients (86 patients per arm) were
required to detect the superiority of EES compared with
DEB (power of 80%; alpha error of 5%). A total of 190
patients were eventually estimated, to be able to accom-
modate a dropout rate of w10% in the late angiographic
study. Analyses were performed according to the intention
to treat principle unless otherwise speciﬁed. SPSS version
15.00 statistical software was used. A p value <0.05 was
considered statistically signiﬁcant.
Results
From January 2010 to January 2012, 189 patients with
BMS-ISR were enrolled in the study (95 allocated to DEB
and 94 to EES) (Fig. 1). Baseline clinical characteristics
were well matched in the 2 groups, except for a higher
frequency of elderly patients and a lower rate of smokers in
the DEB arm (Table 1). Baseline angiographic ﬁndings
were similar in both groups, although lesions in the EES
arm tended to be more severe (Table 1). Procedural success
was obtained in all patients, although 8 patients (8%) in the
DEB arm eventually required stent implantation (DES in
7 patients) as a result or suboptimal results or signiﬁcant
coronary dissections. All patients in the EES arm success-
fully received the allocated stent.
On quantitative coronary angiography, acute angiographic
results were better in the EES arm. Patients treated with
EES obtained a larger minimal lumen diameter (2.38  0.5
mm vs. 2.16  0.5 mm, respectively), a lower residual ste-
nosis (11  11% vs. 19  11%, respectively), and a larger
acute gain (1.45  0.5 vs. 1.14  0.6, respectively; all
189 Pts BMS ISR
Randomization
Inclusion Criteria
Informed Consent
Rx Centralized
Stratification: 
ISR Length & Edge
94 Pts
EES
95 Pts
DEB
3 Died
1 Thrombosis
7 Refused
86 Pts
Angio FU
8 Refused
84 Pts
Angio FUMean: 271 days Mean: 270 days
(170 Pts: 92% of Eligible)
QCA
Primary 
Endpoint
100% Angiographic Success 
Angiographic FU
Figure 1
Study Flow Chart Detailing Patients Randomized
and Patients With Late Angiography
BMS ¼ bare-metal stent(s); DEB ¼ drug-eluting balloon(s); EES ¼ everolimus-
eluting stent(s); FU ¼ follow-up; ISR ¼ in-stent restenosis; Pts ¼ patients;
QCA ¼ quantitative coronary angiography; Rx ¼ prescription.
Table 1
Baseline Clinical, Angiographic, and
Procedural Characteristics
DEB
(n ¼ 95)
EES
(n ¼ 94)
p
Value
Age, yrs 67  11 64  12 0.04
Female 13 (14) 12 (13) 0.85
Risk factors
Diabetes mellitus 30 (32) 19 (20) 0.08
Hyperlipidemia 69 (73) 62 (66) 0.32
Hypertension 68 (72) 68 (72) 0.91
Ever smoked 56 (59) 70 (75) 0.02
Clinical features 0.74
Unstable angina 38 (40) 42 (45)
Stable angina 43 (45) 41 (44)
Silent ischemia 14 (15) 11 (12)
Previous myocardial
infarction
57 (60) 56 (60) 0.95
Previous bypass surgery 4 (4) 7 (7) 0.34
>1 intervention on
target lesion
6 (6) 2 (2) 0.28
Time to restenosis,
days (range)
390
(142–2,815)
350
(151–2,679)
0.78
Ejection fraction, % 58  13 59  12 0.71
Target arteries 0.72
Left anterior descending 35 (37) 37 (39)
Left circumﬂex 21 (22) 22 (23)
Right coronary 37 (39) 32 (34)
Saphenous vein graft 2 (2) 3 (3)
Procedural characteristics
Length of the previous
stent, mm
19  6 18  6 0.51
Length of current
EES/DEB, mm
20  7 23  9 0.01
Maximal pressure, atm 18  4 19  3 0.08
IVUS or OCT 22 (23) 31 (33) 0.14
Balloon-to-artery ratio 1.25  0.2 1.23  0.2 0.52
Cross-over 8 (8) 0 (0) 0.007
Angiographic successes 95 (100) 94 (100) 1.00
Values are mean  SD or n (%) unless otherwise speciﬁed.
DEB ¼ drug-eluting balloon(s); EES ¼ everolimus-eluting stent(s); IVUS ¼ intravascular ultra-
sound; OCT ¼ optical coherence tomography.
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1381p < 0.01) (Table 2). Late angiographic studies (median 249
days) were obtained in 170 patients (92% of those eligible
[excluding 3 patients who died and 1 who experienced stent
thrombosis before late angiography]). At late follow-up,
minimal lumen diameter in the in-segment analysis (the
primary study endpoint) was larger (2.36  0.6 mm vs. 2.01
 0.6 mm, respectively, p < 0.001; absolute mean differ-
ence: 0.35 mm, 95% CI: 0.16 to 0.53), and the percent
diameter stenosis was lower (13  17% vs. 25  20%,
respectively, p < 0.001) in the EES arm than in the DEB
arm. Differences in minimal lumen diameter in favor of
EES persisted (absolute mean difference: 0.29 mm, 95% CI:
0.18 to 0.55, p < 0.001), despite adjustment for imbalances
in baseline characteristics (including age, diabetes, smoking,
and percent of stenosis diameter). In addition, the net
lumen gain (1.41  0.6 mm vs. 0.99  0.6 mm, respectively,
p < 0.001) was also larger in the EES arm (Table 2).
However, the angiographic late loss (mean 0.14  0.5 mm
[DEB] vs. 0.04  0.5 mm [EES]; median 0.07 mm [0.16
to 0.33 mm] vs. 0.001 mm [0.21 to 0.19 mm], p ¼ 0.14)
and the binary restenosis rate (8 [9.5%] vs. 4 [4.7%],
respectively, p ¼ 0.22) were similar in both groups (Table 2).
Overall, angiographic results of the in-lesion analysis were
largely similar to those found in the in-segment analysis
(Table 2). Results were also similar in the per-protocol
analysis. Cumulative frequency distribution curves of mini-
mal lumen diameter and percent diameter stenosis at
different time intervals are shown in Figures 2 and 3.
Notably, the results of the primary endpoint were consistent
across 10 pre-speciﬁed patient and lesion subsets after
formal interaction testing (Fig. 4).
Table 3 summarizes all major adverse clinical events
during hospitalization, at 9 months, and at 1 year. Duringhospital stay, 4 patients (all in the EES arm) experienced a
periprocedural myocardial infarction (3 as the result of a
side-branch loss), but no patient died or required repeated
coronary interventions at the target vessel (Table 3). By late
follow-up, 4 patients died (all in the DEB group), 1 from
cardiac cause and 3 from noncardiac causes. The rates
of myocardial infarction were similar in both groups. Only
1 patient in the DEB arm experienced deﬁnitive stent
thrombosis (due to clopidogrel discontinuation), which
presented as a myocardial infarction requiring urgent
revascularization. No cases of probable stent thrombosis
were found. The rates of target vessel revascularization were
low and similar in both groups, although a trend was found
in favor of the EES arm on target lesion revascularization.
The occurrence of major adverse events and the rate of
major cardiac adverse events were similar in both groups
(Table 3). Estimates of event-free survival are presented in
Figure 5.
Table 2 Angiography Results
DEB EES p Value
Qualitative features (n ¼ 95) (n ¼ 94)
Mehran class I, II, III–IV 38 (40), 45 (47), 12 (13) 34 (36), 42 (45), 18 (19) 0.54
B2-C lesion 48 (51) 51 (54) 0.61
Edge ISR 6 (6) 7 (7) 0.76
Quantitative ﬁndings before the procedure (n ¼ 95) (n ¼ 94)
Reference vessel diameter, mm 2.64  0.6 2.64  0.6 0.96
Minimal lumen diameter, mm 1.02  0.4 0.93  0.4 0.12
Stenosis, % of lumen diameter 61  14 65  13 0.05
Lesion length, mm 13.7  7 13.8  6 0.96
Diffuse lesions >10 mm 58 (62) 66 (71) 0.18
Quantitative ﬁndings after the procedure, in segment (n ¼ 95) (n ¼ 94)
Reference vessel diameter, mm 2.69  0.6 2.68  0.5 0.94
Minimal lumen diameter, mm 2.16  0.5 2.38  0.5 0.001
Stenosis, % of lumen diameter 19  11 11  11 <0.001
Acute gain, mm 1.14  0.6 1.45  0.5 <0.001
Quantitative ﬁndings after the procedure, in lesion (n ¼ 95) (n ¼ 94)
Reference vessel diameter, mm 2.69  0.6 2.76  0.5 0.39
Minimal lumen diameter, mm 2.20  0.5 2.50  0.4 <0.001
Stenosis, % of lumen diameter 18  11 9  13 <0.001
Acute gain, mm 1.17  0.6 1.57  0.5 <0.001
Quantitative ﬁndings at follow-up, in segment (n ¼ 84) (n ¼ 86)
Reference vessel diameter, mm 2.70  0.5 2.73  0.5 0.60
Minimal lumen diameter, mm 2.01  0.6 2.36  0.6 <0.001
Stenosis, % of lumen diameter 25  20 13  17 <0.001
Binary restenosis 8 (9.5) 4 (4.7) 0.22
Mean/median late loss mm 0.14  0.5/0.07 (0.16 to 0.33) 0.04  0.5/0.001 (0.21 to 0.19) 0.14
Mean/median loss index 0.06  0.6/0.07 (0.14 to 0.33) 0.002  0.4/0.001 (0.15 to 0.14) 0.13
Net gain, mm 0.99  0.6 1.41  0.6 <0.001
Quantitative ﬁndings at follow-up, in lesion (n ¼ 84) (n ¼ 86)
Reference vessel diameter, mm 2.70  0.5 2.81  0.5 0.18
Minimal lumen diameter, mm 2.03  0.6 2.44  0.6 <0.001
Stenosis, % of lumen diameter 24  20 13  15 <0.001
Binary restenosis 8 (9.5) 4 (4.7) 0.22
Values are n (%) or mean  SD unless otherwise speciﬁed.
DEB ¼ drug-eluting balloon(s); EES ¼ everolimus-eluting stent(s); ISR ¼ in-stent restenosis.
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Figure 2
Cumulative Frequency Distribution Curves of
Minimal Lumen Diameters
Minimal lumen diameters (MLDs) are shown before the procedure (PRE), after the
intervention (POST), and at late follow-up (FU) (dashed lines).
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1382Discussion
This randomized clinical trial supports the value of DEB
and EES in patients with BMS-ISR. Both therapeutic
strategies were associated with excellent 1-year clinical out-
comes. In particular, the appearance of clinical restenosis and
the need for target vessel revascularization were very low and
similar in the 2 groups. Furthermore, late angiographic
ﬁndings were also excellent in the 2 arms, with single digit
ﬁgures of binary angiographic restenosis and a very low
angiographic late loss. However, late angiographic results
were superior in the EES arm. Indeed, minimal lumen
diameter (the primary endpoint of the study), the percent
of diameter stenosis, and the net angiographic gain were
signiﬁcantly better in the EES arm. The consistency of these
ﬁndings was supported by the uniform effect found across all
pre-speciﬁed patient and lesion subsets.
The larger acute gain obtained after EES appears to
explain the better late angiographic results achieved in this
arm as late loss was very low and similar in both groups.
(%) Stenosis 
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Figure 3
Cumulative Frequency Distribution Curves of
Diameter Stenosis
Cumulative frequency distribution curves of the percentages of diameter stenosis
before the procedure (PRE), after the intervention (POST), and at late follow-up (FU)
(dashed lines) are shown. The intersection of the green line (50%) with the
distribution curves at FU (dashed lines) determined the binary restenosis (RE)
rates in both arms.
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1383However, the superior late angiographic ﬁndings seen in the
EES arm did not translate into improved long-term clinical
outcomes compared with the DEB arm. This may be
explained by the excellent late angiographic results also seen
in the DEB arm. Patients treated with DEB obtained a
lower acute gain but beneﬁted from a uniquely small
angiographic late loss during follow-up. Indeed only 9.5% of
these patients developed angiographic restenosis, and only
6% required repeat revascularization at 1-year follow-up.
These ﬁndings demonstrate that, from a clinical stand-
point, both strategies are highly effective in this scenario.All
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Figure 4
Analysis of Absolute Difference of Minimal Lumen
Diameter at Follow-Up in the 10 Pre-Speciﬁed
Variables
All interaction tests were negative (p Inter). AMD ¼ absolute mean difference, mm;
B/A ¼ balloon/artery ratio; LAD ¼ left anterior descending coronary artery; MLD ¼
minimal lumen diameter; Mo ¼ month; UA ¼ unstable angina; other abbreviations
as in Figure 1.Our study was unable to ﬁnd differences in the composite
clinical outcome measure and was largely underpowered to
detect differences in individual events, including repeat
revascularization. Nevertheless, we cannot exclude the fact
that the superior angiographic ﬁndings obtained with EES
might eventually translate into a clear net clinical beneﬁt.
Classical studies of ﬁrst-generation DES suggest that below
a given late loss (<0.5 mm), this angiographic parameter is
no longer predictive of the clinical need for target lesion
revascularization during follow-up (23). It was suggested
that these relatively large residual lumens were able to pro-
vide enough “room” to prevent any clinical consequences
(23). However, subsequent larger studies and meta-analysis
have demonstrated that even minor differences in late
angiographic ﬁndings eventually translated into different
clinical outcomes, driven mainly by repeated revasculariza-
tion rates (24). In this regard, the trends toward a lower rate
of target vessel and target lesion revascularization in the EES
arm are of interest. Therefore, further studies, including
larger series of patients or extended follow-up periods
(powered to detect differences in individual clinical end-
points), are needed to examine this intriguing possibility.
Previous studies. A classical study (11) demonstrated that
in patients with BMS-ISR, DEB were superior to balloon
angioplasty alone. In that small but pivotal study, patients
were randomly allocated to receive DEB (n ¼ 26) or balloon
angioplasty (n ¼ 26). Late angiographic results were supe-
rior in the DEB arm (minimal lumen diameter: 2.22  0.57
mm; late loss: 0.03  0.48 mm), with no episodes of repeat
revascularization at 1 year. Subsequently, another random-
ized trial compared DEB (n ¼ 66) with paclitaxel-eluting
DES (n ¼ 65) in patients with BMS-ISR (12). At
follow-up, DEB were able to reduce the late loss but pro-
vided a minimal lumen diameter (0.17  0.42 mm and 2.03
 0.56 mm, respectively) similar to that of paclitaxel-eluting
DES.
The value of DEB in patients with DES-ISR has also
been established (13–16). A small single-center randomized
study demonstrated that in patients with limus-DES-ISR,
DEB were superior to balloon angioplasty (13). Subse-
quently, a multicenter randomized trial (14) conﬁrmed the
superiority of DEB compared with balloon angioplasty in
patients with DES-ISR. The ISAR-DESIRE 3 (Intra-
coronary Stenting and Angiographic Results: Drug Eluting
Stents for In-Stent Restenosis 3) multicenter randomized
trial (15) investigated the efﬁcacy of DEB, paclitaxel-eluting
DES, and balloon angioplasty in patients with limus-eluting
DES-ISR. A late loss of 0.37 mm was found in the DEB
arm. The study demonstrated noninferiority of DEB
compared with paclitaxel-eluting DES but also the superi-
ority of these 2 strategies compared with balloon angioplasty
(15). Finally, a recent randomized study suggested that DEB
are more effective in patients with BMS-ISR than in those
with DES-ISR (16). This would explain the larger late
loss seen after DEB for DES-ISR in all previous studies
(11–16).
Table 3 Major Adverse Clinical Events
DEB (n ¼ 95) EES (n ¼ 94) p Value RR/HR (95% CI)
Hospital events RR (95% CI)
Death 0 (0) 0 (0) 1.00 d
Cardiac death 0 (0) 0 (0) 1.00 d
Myocardial infarction 0 (0) 4 (4) 0.06 d
Target lesion revascularization 0 (0) 0 (0) 1.00 d
Target vessel revascularization 0 (0) 0 (0) 1.00
Coronary angioplasty 0 (0) 0 (0) 1.00 d
Coronary surgery 0 (0) 0 (0) 1.00 d
Composite MACE 0 (0) 4 (4) 0.06 d
Events at 9 months HR (95% CI)
Death 3 (3) 0 (0) 0.38 d
Cardiac death 0 (0) 0 (0) 1.00 d
Myocardial infarction 2 (2) 4 (4) 0.41 2.06 (0.38–11.2)
Target lesion revascularization 4 (4) 0 (0) 0.31 d
Target vessel revascularization 4 (4) 1 (1) 0.21 0.25 (0.03–2.20)
Coronary angioplasty 4 (4) 1 (1) 0.21 0.25 (0.03–2.20)
Coronary surgery 0 (0) 0 (0) 1.00 d
Composite MACE 5 (5) 5 (5) 0.97 1.02 (0.30–3.53)
Events at 1 yr
Death 4 (4) 0 (0) 0.31 d
Cardiac death 1 (1) 0 (0) 0.61 d
Myocardial infarction 3 (3) 4 (4) 0.68 1.37 (0.31–6.11)
Target lesion revascularization 6 (6) 1 (1) 0.09 0.16 (0.02–1.32)
Target vessel revascularization 6 (6) 2 (2) 0.17 0.32 (0.07–1.59)
Coronary angioplasty 6 (6) 2 (2) 0.17 0.32 (0.07–1.59)
Coronary surgery 0 (0) 0 (0) 1.00 d
Composite MAE 11 (12) 6 (6) 0.24 0.55 (0.20–1.49)
Composite MACE 8 (8) 6 (6) 0.60 0.76 (0.26–2.18)
Values are n (%) unless otherwise speciﬁed. Patients with more than 1 event were counted only once for the composite clinical endpoint, although
each event was listed separately in the corresponding category. p values were obtained from Cox analysis.
CI ¼ conﬁdence interval; FU ¼ follow-up; HR ¼ hazard ratio (events at follow-up); MACE ¼major adverse cardiac events (cardiac death, myocardial
infarction, target vessel revascularization); MAE ¼major adverse events (death, myocardial infarction, target vessel revascularization); RR¼ risk ratio
(hospital events); other abbreviations as in Tables 1 and 2.
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trials strongly suggest that DEB are superior to conventional
balloon angioplasty and similar to ﬁrst-generation DES in
patients with BMS- or DES-ISR (11–16). Interestingly, in
all of these studies, only a speciﬁc DEB, using iopromide as
a hydrophilic spacer, was used (11–16). Likewise, only
paclitaxel-eluting DES were used in the comparator arm
(12,15). However, until now, whether new-generation DES
are superior to DEB in patients with ISR remained un-
known. Accordingly, the purpose of the current study was to
compare DEB with a second-generation EES for the indi-
cation of BMS-ISR.
New insights on the treatment of in-stent restenosis.
The use of second-generation DES in this setting appears
particularly attractive (17–19). Many previous randomized
studies and meta-analyses suggested that in “de novo” lesions,
EES are not only more effective but also safer than ﬁrst-
generation DES (17–19). However, data supporting the
value of the new DES in patients with ISR are scarce. In a
previous prospective multicenter registry (8), we found that in
patients presenting with DES-ISR, second-generation DES
were more effective than ﬁrst-generation DES. The use of
EES in patients with ISR is highly appealing to ensureoptimal acute results and subsequently beneﬁt from their
powerful antirestenosis properties (17–19). In this scenario,
DEB are also very effective and therefore provide an attractive
comparator (11–16). The present study represents the ﬁrst
controlled clinical trial comparing DEB versus EES in pa-
tients with BMS-ISR. Both strategies were associated with
excellent and similar late clinical outcomes. However, our
study demonstrated that EES are able to provide superior late
angiographic ﬁndings. EES maximize acute lumen gain and
minimize late loss, therefore providing uniquely favorable late
angiographic results.
From a methodological perspective, some issues deserve
further consideration. The classical endpoint of angiographic
late loss is not appropriate for comparisons of strategies that
provide different acute gains (i.e., balloons and stents), as the
acute gain directly inﬂuences the late angiographic loss and
clinical restenosis is best reﬂected by a variable that reﬂects
both acute diameter increase and late injury response (2,4).
The loss index provides some mechanistic insights as it takes
into account the acute gain. However, we selected the
minimal lumen diameter at follow-up as the primary
endpoint for the efﬁcacy analysis. This is a more clinical-
oriented endpoint that in our study was closely related to
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Figure 5 Kaplan-Meier Estimates of the Event-Free Survival
(A) Estimates are shown for freedom from major adverse cardiac events (MACE) (e.g., cardiac death, myocardial infarction [MI] and target vessel revascularization [TVR]).
(B) Estimates are shown for freedom from major adverse events (MAE) (death, MI, TVR). DEB ¼ drug-eluting balloon(s); EES ¼ everolimus-eluting stent(s).
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On the other hand, geographic miss may represent a prob-
lem with both DES and DEB (2,4,11,12). However, we did
not observe signiﬁcant edge-effects (similar results in the in-
lesion and -segment analyses), probably due to our careful
protocol aimed at preventing this phenomenon. Finally, our
study was unable to ﬁnd differences in the combined clinical
endpoint, and it was largely underpowered to compare in-
dividual endpoints. However, some clinical signals merit
further discussion. All 4 deaths occurred in the DEB arm,
but 3 of them were noncardiac related. Likewise, the 4
procedure-related myocardial infarctions were seen in the
EES arm, and 3 of them were related to a side-branch loss
on angiography. Whether repeat stent implantation has a
higher risk for this complication compared with DEB
warrants additional studies, although this phenomenon was
not detected in previous studies of repeat stenting (2,4).
Finally, although the rates of target lesion revascularization
were similar in both groups, there was a trend toward a lower
rate of target lesion revascularization after EES. This signal
is consistent with the differences in the late angiographic
ﬁndings, but, considering the low number of events and the
similar rates of angiographic restenosis, this should be
interpreted with great caution and would require conﬁrma-
tion by additional studies.
An important ﬁnding of the current study was the excel-
lent late angiographic results seen after DEB, in keeping with
previous DEB studies in this setting (11–16). Indeed, the late
loss after DEB (only 0.14 mm) was drastically reduced
compared with the late loss found in the RIBS I (0.73 mm)
(2) and II (0.69 mm) (4) studies that used conventional
balloon angioplasty in patients with BMS-ISR. Therefore,
for the ﬁrst time (10), we have in our armamentarium2 simple yet highly effective therapeutic modalities to offer
to patients presenting with BMS-ISR. EES provide better
late angiographic results but pay the price of a new metal
layer (25). Alternatively, DEB obviate the need for an
additional metal layer but result in inferior late angiographic
ﬁndings compared with EES. We were unable to identify
clinical or angiographic features that could be used to favor
1 of these therapies over the other in selected patients.
However, it is clear that the better angiographic results
provided by DES are particularly attractive in patients with
ISR. Alternatively, in a real-world clinical setting, one may
speculate that DEB may be preferred over EES in patients
who already have multiple metal layers at the lesion site, in
those with ISR encompassing large side branches, and in
those who are at higher risk for bleeding complications from
a prolonged dual antiplatelet regimen. Further studies will be
required to identify patients more likely to beneﬁt from each
intervention.
Study limitations. First, studies with protocol-mandated
late angiographic assessment may overestimate the rate of
repeat revascularization. However, our study emphasized the
need for a clinical indication before proceeding with any
reintervention, and actually, repeat revascularization rates
were very low. Second, our trial was not powered to detect
differences in individual clinical endpoints (including
revascularization) between the 2 groups. Larger studies with
longer follow-up will be required to further establish the late
clinical and angiographic outcomes with these therapeutic
strategies. Third, although the value of intracoronary imaging
(intravascular ultrasound or optical coherence tomography)
has been suggested for use in patients with ISR, these tools
were not systematically used in the present study. It remains
possible, however, that aggressive procedural optimization
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results of these interventions, particularly in the DEB arm.
Fourth, we used only a particular DEB-releasing paclitaxel
from an iopromide excipient. Accordingly, our ﬁndings might
not be generalizable to other DEB as they may have variable
efﬁcacy. Finally, we did not include patients with DES-ISR.
Previous studies have suggested that treatment of those pa-
tients is particularly challenging (16). Moreover, the results of
second-generation DES in those patients remain to be
determined. The currently ongoing RIBS IV trial (DEB vs.
EES in patients with DES-ISR) will determine the relative
efﬁcacy of these therapeutic strategies in patients with DES-
ISR.
Conclusions
This randomized clinical trial suggests that in patients with
BMS-ISR, both DEB and EES provide excellent clinical
results with a very low rate of clinical and angiographic re-
currences. However, compared with DEB, EES provide
superior late angiographic ﬁndings.
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